Outlook TherapeuticsXTER:41O 19 EV-to-FCF is -8.25 as of Jul. 11, 2026. GuruFocus rates XTER:41O with a GF Score™ of 19/100. The stock has 6 warning signs investors should review. Among 330 Biotechnology companies, Outlook Therapeutics ranks worse than 303030% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Outlook Therapeutics's Enterprise Value is €333.07 Mil.
Outlook Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €-40.39 Mil. Therefore, Outlook Therapeutics's EV-to-FCF for today is -8.25.
The historical rank and industry rank for Outlook Therapeutics's EV-to-FCF or its related term are showing as below:
XTER:41O'
s EV-to-FCF Range Over the Past 10 Years
Min: -8.89 Med: -1.9 Max: 0.38
Current: -5.72
During the past 12 years, the highest EV-to-FCF of Outlook Therapeutics was 0.38. The lowest was -8.89. And the median was -1.90.
XTER:41O's EV-to-FCF is ranked worse than 100% of 330
companies
in the Biotechnology industry
Industry Median: 16.36
vs XTER:41O: -5.72
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Outlook Therapeutics (XTER:41O) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Outlook Therapeutics's PE Ratio (TTM) for today is calculated as:
Outlook Therapeutics's share price for today is €0.00.
Outlook Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Outlook Therapeutics EV-to-FCF Related Terms
Outlook Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Outlook Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:41O vs FULC, OBIO, ACIU: EV-to-FCF Comparison
For the Biotechnology subindustry, Outlook Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Outlook Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Outlook Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Outlook Therapeutics's EV-to-FCF falls into.
Outlook Therapeutics's current Enterprise Value is €333.07 Mil.
Outlook Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-40.39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Outlook Therapeutics (XTER:41O) has a EV-to-FCF of -8.25 as of Jul. 11, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Outlook Therapeutics and its competitors. According to the industry distribution chart, Outlook Therapeutics ranks #999999 out of 330 companies in the Biotechnology industry.
Is Outlook Therapeutics' EV-to-FCF too high?
Outlook Therapeutics' current EV-to-FCF is -8.25. Based on the distribution chart, Outlook Therapeutics ranks #999999 out of 330 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Outlook Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Outlook Therapeutics' EV-to-FCF compare to FULC and OBIO?
According to the Biotechnology industry distribution chart, Outlook Therapeutics ranks #999999 out of 330 companies for EV-to-FCF. This places Outlook Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 16.36. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.36, based on 330 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Outlook Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Outlook Therapeutics's current EV-to-FCF is -8.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Outlook Therapeutics stock overvalued right now?
Outlook Therapeutics (XTER:41O) has a current EV-to-FCF of -8.25. The current EV-to-FCF is -8.25. Outlook Therapeutics' overall GF Score™ is 19/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Outlook Therapeutics (XTER:41O), the current EV-to-FCF is -8.25 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:41O has been successfully added to your 